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MigrationThemembers of p90 ribosomal S6 kinase (RSK) family of Ser/Thr kinases are downstream effectors ofMAPK/ERK
pathway that regulate diverse cellular processes including cell growth, proliferation and survival. In carcinogen-
esis, RSKs are thought tomodulate cellmotility, invasion andmetastasis. Herein, we have studied an involvement
of RSKs in FGF2/FGFR2-driven behaviours of mammary epithelial and breast cancer cells. We found that both
silencing and inhibiting of FGFR2 attenuated phosphorylation of RSKs, whereas FGFR2 overexpression and/or
its stimulationwith FGF2 enhanced RSKs activity.Moreover, treatment with ERK, Src and p38 inhibitors revealed
that p38 kinase acts as an upstream RSK2 regulator.We demonstrate for the ﬁrst time that in FGF2/FGFR2 signal-
ling, p38 but not MEK/ERK, indirectly activated RSK2 at Tyr529, which facilitated phosphorylation of its other
residues (Thr359/Ser363, Thr573 and Ser380). In contrast to FGF2-triggered signalling, inhibition of p38 in the
EGF pathway affected only RSK2-Tyr529, without any impact on the remaining RSK phosphorylation sites.
p38-mediated phosphorylation of RSK2-Tyr529 was crucial for the transactivation of residues located at kinase
C-terminal domain and linker-region, speciﬁcally, in the FGF2/FGFR2 signalling pathway. Furthermore, we
show that FGF2 promoted anchorage-independent cell proliferation, formation of focal adhesions and cell migra-
tion,whichwas effectively abolished by treatmentwith RSKs inhibitor (FMK). These indicate that RSK2 activity is
indispensable for FGF2/FGFR2-mediated cellular effects. Our ﬁndings identiﬁed a new FGF2/FGFR2-p38-RSK2
pathway, which may play a signiﬁcant role in the pathogenesis and progression of breast cancer and, hence,
may present a novel therapeutic target in the treatment of FGFR2-expressing tumours.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Cancer cell migration is fundamental to tumour progression and
metastatic spreading. Tumour cells acquire migratory capacities during
transformation; however, to progress into invasive cancer, they require
support from the surrounding stroma mediated by various growth
factors and their signalling pathways.
RSK (ribosomal S6 kinase) is a family of serine/threonine kinases
consisting inhumanof four isoformsRSK1-4 and twostructural relatedho-
mologues called MSK1-2 (mitogen and stress activated kinase). The RSKs
share structural and functional similarities and are 73%–80% identical atathology, Medical University of
lar Enzymology, Intercollegiate
edical University of Gdańsk,
Romanska),
. This is an open access article underthe amino acid level [1]. Thepresence of twodistinct, C-terminal kinasedo-
main (CTKD) andN-terminal kinasedomain (NTKD), connectedbya linker
region is a characteristic feature of RSK family [2,3]. CTKD is responsible for
autophosphorylation andRSKs activation in response to extracellular stim-
uli, whereas NTKD phosphorylates downstream effectors (mainly tran-
scription factors) involved in a broad range of cellular activities including
differentiation, survival, proliferation, growth and migration [3–5].
The signiﬁcance of RSK family members for carcinogenesis is just
being appreciated. Of the four isoforms, RSK1 and RSK2 are the best
characterized. In most biological contexts studied so far, RSK2 has
been shown to promote metastasis, whereas the role of other RSK iso-
forms appears to be cell-type speciﬁc [6]. The overexpression of RSK1
and RSK2 has been associated with multiple types of epithelial as well
as hematologic malignancies [7,8]. Their level was found to be elevated
in ~50% of breast tumours [9], and the overexpression of RSK2 was
shown to be associated with shorter disease-free survival [10]. In head
and neck squamous cell carcinoma (HNSCC), RSK2 was correlated
with metastatic progression and poor patient survival [11]. In highlythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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knockdown was shown to reduce metastasis in an animal model. On the
other hand, silencing of RSK1 in HNSCC cells did not affect their
invasiveness [11]. However, RSK1was demonstrated to be a negative reg-
ulator of non-small cell lung cancer progression, inwhichRSK1expression
was shown to be decreased in secondary versus primary lesions. The
knockdown of RSK1 led to the enhancement of cell migration (the knock-
down of RSK2 and RSK4 had an opposite effect) and in vivo formation of
metastases by A549 lung cancer cells [12]. In contrast, the overexpression
of RSK1 in melanoma cell lines was found to increase cell motility [13].
RSKs are located downstream of the MAPK/ERK pathway and acti-
vated in response to several growth factors and mitogens, including
EGF [14,15], insulin [16] and IGF-1 [17]. The currently accepted model
of RSKs activation proposes that upon stimulation, active ERK binds to
CTKD and phosphorylates RSKs at Thr573 in the CTKD, together with
Ser363 and Thr359 in the linker region. Subsequently, activated CTKD
phosphorylates Ser380 in the linker region, which recruits PDK1. This
is followed by phosphorylation of Ser221 in NTKD by PDK1, which
allows RSKs to regulate function of its substrates [1,18]. Activated
RSKs control the activity of multiple nuclear proteins, including
transcription factors YB-1 [19], c-Fos [20], CREB [15] and p53 [21].
A genome-wide mRNA analysis revealed that ERK/RSK signalling
affects the expression of over 50 genes from diverse pathways re-
sponsible for cell motility and invasiveness [22]. Alternative path-
ways of RSKs activation, including those mediated by ﬁbroblast
growth factor (FGF) receptors, are being currently revealed. For
example, RSK2 has been reported to be directly phosphorylated at
Tyr529 by FGFR3 [23]. An interaction between RSK1 and FGFR2 (or
KGFR) has been implicated in FGFR2-induced AKT activation in epithe-
lial cells [24]. Therefore, various, yet unravelled, interrelations between
members of FGFR and RSK families are likely to be of functional conse-
quences for cell behaviour.
FGFR2 and its ligands (e.g., FGF2) have been proved to play an
important role in breast cancer (BCa) development and progression.
Genome-wide analysis has identiﬁed four SNPs (single nucleotide poly-
morphism) in the intron 2 of FGFR2 gene, whichwere associatedwith a
higher incidence of BCa [25]. Moreover, the activation of FGFR2
triggered aggressive growth of breast cancer cells in vivo [26]. FGFR2 is
suggested to be essential for induction of self-renewal and cell mainte-
nance of human breast tumour initiating cells (TIC). TICs were shown to
be enriched in FGFR2-expressing population of BCa cells [27]. FGF2
(basic FGF, bFGF) was found to be widely distributed in numerous
tumours [28] and associated with cancer development by promoting
epithelial cell proliferation and angiogenesis [reviewed in 29]. Addition-
ally, FGF2 was shown to increase in vitro migration and invasion of
various breast cancer cell lines (MDA-MB-231, Bcap-37, MCF10DCIS
and MCF7) [30,31], partially via stimulation of secretion of matrix
metalloproteinase-9 (MMP-9) [32].
FGF2 has been found in cytoplasm of BCa cells [33] as well as in
tumour stroma [34] and shown, similarly to other members of FGF
family, to generate signal by activating FGFR2 either in autocrine or
paracrine manner. Importantly, the assessment of elevated FGF2 level
in nipple aspirates has been suggested to be a potential diagnostic test
for breast cancer [35]. By analogy with prostate cancer, where FGFR2-
overexpressing epithelial cells were shown to be stimulated by FGF2-
secreting cancer-associated ﬁbroblasts [36], a paracrine action of FGF2
might play an essential role in BCa progression.
Herein, we demonstrate for the ﬁrst time that in normal mammary
epithelial and breast cancer cell lines, signalling triggered by FGF2/
FGFR2 leads to the activation of RSK2 at Tyr529 mediated indirectly by
p38 kinase, which is followed by the activation of other residues of
the RSK kinase. Furthermore, we show that RSK2 mediates FGF2-
stimulated anchorage-independent growth, formation of focal adhe-
sions (FA) and cell migration. These results implicate the FGFR2/FGF2-
p38-RSK2 signalling pathway in cell migration and breast cancer
progression and might be of important clinical signiﬁcance.2. Material and methods
2.1. Cell lines, antibodies and reagents
HB2 cells were kindly donated by Dr. F. Berditchevski, University of
Birmingham, UK. All other cell lines were obtained from ATCC. Cells
were grown as follows: (i) MCF7, MDA-MB-361, MDA-MB-231 and
SKBR3 in DMEM supplemented with 10% fetal bovine serum (FBS);
(ii) HB2 in DMEMwith 10% FBS, 5 μg/ml insulin and 5 μg/ml hydrocor-
tisone; (iii) BT474 in RPMI-1640 with 10% FBS and 5 μg/ml insulin; and
(iv) MCF10A in DMEM Ham's F-12 with 5% horse serum, 20 ng/ml EGF,
100ng/ml cholera toxin, 0.5 μg/ml hydrocortisone and 10 μg/ml insulin.
All cell culture media were supplemented with penicillin/streptomycin
(100 U/ml/100 μg/ml). All media and their supplements were pur-
chased from Sigma-Aldrich. The following antibodies were obtained
from Santa Cruz Biotechnology: anti-EGFR (sc-03), anti-FAK (sc-558),
anti-FGFR1 (sc-121), anti-FGFR2 (sc-122), anti-FGFR4 (sc-124), anti-
FRS2 (sc-17841), anti-paxillin (sc-5574) and anti-Src (sc-18). Antibody
against β-actin (A5316) was obtained from Sigma-Aldrich. All the
remaining antibodies used in this study were from Cell Signaling
Technology: anti-Akt (#9272), anti-Akt-Ser473 (#4048), anti-EGFR-
Tyr1068 (#3777), anti-ERK1/2 (#4695), anti-ERK1/2-Thr202/Tyr204
(#9101), anti-FAK-Tyr397 (#3283), anti-FGFR-Tyr653/654 (#3471),
anti-FRS2α-Tyr436 (#3861), anti-paxillin-Tyr118 (#2541), anti-
PLCγ1-Tyr783 (#2821), anti-p38 (#9212), anti-p38-Thr180/Tyr182
(#9211), anti-RSK1/RSK2/RSK3 (#9335), anti-RSK2 (#5528), anti-
RSK2-Tyr529 (#9324), anti-RSK-Ser380 (#9335), anti-RSK-Thr359/
Ser363 (#9344), anti-RSK-Thr573 (#9346) and anti-Src-Tyr416
(#2101). All growth factors were obtained from PeproTech. Heparin
sodium salt and following inhibitors: PD173074, U120, SU6656 and
SB202190, were purchased from Sigma-Aldrich. FMK was from
AxonMedchem.
2.2. Western blotting
Cells grown to 80%–90% of conﬂuency were lysed with Laemmli
buffer (2× concentrated) containing 2 mM PMSF, 10 μg/ml aprotinin,
10 μg/ml leupeptin, 5 mM EGTA, 1 mM EDTA, 2 mM Na4P2O7, 5 mM
NaF and 5 mM Na3VO4. Samples containing equal amounts of protein
per lane were loaded, resolved in SDS–PAGE and then transferred
onto nitrocellulose membrane. The membranes were incubated for
1 h in 5% skimmed milk and probed with speciﬁc antibodies overnight
at 4 °C. Secondary antibodies conjugated with HRP (Sigma-Aldrich)
and Western Lightning Plus-ECL (PerkinElmer) were used to visualize
speciﬁc protein bands.
2.3. Soft agarose assay for anchorage-independent growth
The 104 cells per well of 6-well plate were suspended in 3ml of 0.5%
low gelling temperature agarose (Sigma) prepared in DMEM containing
10% FBS and overlaid on 3 ml solidiﬁed 0.6% agarose made up in
the same medium. The top layer was covered with 3 ml of DMEM
(10% FBS) supplemented, when appropriate, with FGF2 (10 ng/ml),
FMK (2 μM) or SB202190 (10 μM). The medium was refreshed every 2
or 3 days. After 21 days of culture, colonies were counted andmeasured
using ZEISS PrimoVert microscope and ImageJ software program.
2.4. Immunoﬂuorescence staining
One day before staining, cells were seeded onto sterile glass cover-
slips. Specimens were ﬁxed with 2% paraformaldehyde in PBS and
permeabilized with 0.1% Triton X-100 in PBS for 1 min. After blocking
with 3% BSA in PBS, cells were incubated with speciﬁc primary antibod-
ies. Antibodies against paxillin (dilution 1:100), FAK (1:100) and RSK2
(1:75) were used. Cells were then stained with AfﬁniPure DyLight
549-conjugated secondary antibodies (Jackson ImmunoResearch). The
Fig. 1. FGFR2 regulates RSKs activity. (A) FGFRs and RSKs expression level in human
mammary epithelial (MCF10A, HB2) and breast cancer cell lines (MCF7, SKBR3, BT474,
MDA-MB-361 and MDA-MB-231). (B) Downregulation of FGFR2 impairs RSKs activity.
The stable knockdown of FGFR2 in SKBR3, HB2 and MDA-MB-361 cells was generated
by FGFR2-speciﬁc shRNA expression plasmids. The knockdown of FGFR2, level of other
FGFRs and downregulation of active forms of RSKs were veriﬁed by Western blotting.
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scope ZEISS AxioVert 200.
2.5. FGFR2 knockdown, the overexpression of FGFR1, FGFR2 and p38
HB2- and SKBR3-FGFR2-negative cell lines were generated using
FGFR2-speciﬁc shRNA expression plasmids obtained from OriGene
Technologies (FGFR2 Human, 4 unique 29mer shRNA constructs in
retroviral RFP vector, #TG320519). Transfections were conducted
using TurboFect Transfection Reagent (Thermo Scientiﬁc) according to
the manufacturer's protocol. Stable cell lines expressing shRNA were
established by puromycin selection followed by ﬂuorescent sorting.
Knock down of FGFR2 was veriﬁed by Western blotting. The overex-
pression of p38, FGFR1 and FGFR2 was achieved by transient trans-
fection with p38HA plasmid (Addgene plasmid 12658) or retroviral
transduction (FGFR1—Addgene plasmid 20486, FGFR2—Addgene
plasmid 45698) and conﬁrmed by Western blotting.
2.6. Migration assay
Transwell migrationwas assayed as previously described [37]. Brief-
ly, HB2 cellswere serum-starved overnightwith/without RSK2 inhibitor
(FMK). Next day cells were detached using Cell Dissociation Solution
(Millipore). The 2 × 105 cells were suspended in serum-free DMEM
with/without RSK2 inhibitor. Cells were then placed in the inner com-
partment of Boyden chamber inserts with polycarbonate uncoated
membranes (8-μmpores, BD Bioscience). Cells were allowed tomigrate
toward DMEM (10% FBS) ± 10 ng/ml FGF2/10 ng/ml heparin sulphate
with/without RSKs inhibitor for 24 h. Non-migrated cells were removed
by cotton swab. Nuclei of migrated cells were stained with DAPI.
Membranes were mounted onto glass slides and analyzed using a
ZEISS AxioVert 200 microscope. Up to twenty random ﬁelds per mem-
brane were photographed and analyzed (cells were counted).
2.7. Stimulation with growth factors, signalling analysis and inhibitory
effects
For analysis of signalling triggered by growth factors, cells were rou-
tinely starved overnight in serum-free media. Where required, media
were supplemented with an appropriate inhibitor: SB202190 (10 μM)
or PD173074 (100 nM). Cells were then stimulated with FGF2 or EGF
(10 ng/ml) for indicated periods of time. In all experiments, FGF2 was
used together with heparin sulphate (10 ng/ml). For inhibitory studies,
U120 (10 μM, Sigma), SU6656 (10 μM, Sigma) or SB202190 (10 μM,
Sigma) were applied for 24 h to the cells and their effects on ERK, Src
or p38 signalling pathways, respectively, were analyzed.
2.8. Statistical analyses
Data are expressed as means ± SD of at least three independent
experiments. Comparative data were analyzed with the unpaired
Student's t-test using the Statistica 7.1 software. The results were
considered statistically signiﬁcant when p was less than 0.05.
3. Results
3.1. FGFR2 regulates the activity of RSKs
It has been previously shown that FGFR3 directly phosphorylates
RSK2 at Tyr529 [23]. The expression of FGFRs was tested in a panel of
mammary epithelial (MCF10A and HB2) and BCa (MCF7, BT474,
SKBR3, MDA-MB-361 and MDA-MB-231) cell lines. Due to high glyco-
sylation of FGFRs, numerous bands were observed in Western-
Blotting. For example, FGFR2 as reported before was detected as both
a 105- and a 110-kDa band, which represents an immature, partially
processed protein present in ER and the early Golgi, and a 130-kDaband of a fully glycosylated mature receptor [38,39]. Results showed
that the expression of speciﬁc FGFRs varied between cell lines, with
FGFR2 reaching the highest levels in HB2 and SKBR3 cells andmoderate
in MCF7 andMDA-MB-361 cells (Fig. 1A). These cell lines were selected
and used for further studies. We found that the knockdown of FGFR2 in
HB2 mammary epithelial, SKBR3 and MDA-MB-361 breast cancer cell
lines strongly decreased the activation of RSK at Tyr529 (antibodies spe-
ciﬁc for RSK2) as well as other common for all RSKs phosphorylation
sites, i.e., Thr573, Ser380 and Thr359/Ser363 (Fig. 1B). Silencing of
FGFR2 has been reported to increase FGFR1 expression in S115 breast
cancer cells [40]. In cell lines used in our study, however, the knock-
down of FGFR2 did not affect expression level of any of the other FGF re-
ceptors. shRNA speciﬁc to FGFR2 did not change either FGFR1 or FGFR4
(FGFR3 was not detectable). In light of emerging role of FGFR2 in neo-
plasia [41,42] and, in particular, in the development and progression
of breast carcinoma [26,27], we went on to investigate the mechanisms
underlying the FGFR2/RSKs interdependence and functional conse-
quences of their cross-talk.
3.2. RSK2 is activated upon FGF2-triggered signalling
All FGFRs are thought to be activated by their ligands by a common
mechanism where heparin/heparin sulphate enables the formation of
an active FGF/FGFR (ligand/receptor) complex [43]. This was the ratio-
nale for all our experiments involving action of FGF2 to be done in the
presence of heparin. FGF binding to the extracellular ligand-binding do-
main of FGFR instigates oligomerization of a ternary complex (FGF/
FGFR/heparin) and leads to autophosphorylation of tyrosine residues
in the cytoplasmic domain of the receptor. FGFR activation facilitates
the recruitment of numerous signalling proteins, particularly PLCγ
(phospholipase Cγ) and FRS2 (FGFR substrate 2). The FRS2 is an adaptor
protein linking MAPK and PI3K/Akt pathways to the activated FGFR
[44]. As expected, analysis of signalling pathways triggered by FGF2 in
three, FGFR2 expressing cell lines: HB2, SKBR3 and MDA-MB-361, has
conﬁrmed the importance of autophosphorylation of the receptor at
tyrosines 653 and 654 for stimulation of receptor kinase's activity and
FGFR-mediated biological responses [45]. The activation of FGFR speciﬁc
effectors, FRS2 and PLCγ, as well as other downstream targets such as
AKT, p38 and ERK, but not Src, has also been observed (Fig. 2A and
Supplementary Fig. 1). Importantly, we found that stimulation with
FGF2 led to the activation of RSKs. Speciﬁcally, RSK was shown to be
phosphorylated at Tyr529 (speciﬁc for RSK2) and at highly conserved
Fig. 2. RSK2 is activated upon FGF2 stimulation. (A) HB2, SKBR3 and MDA-MB-361 cells were starved overnight in serum-free media and stimulated with FGF2 (10 ng/ml) + heparin
sulphate (10 ng/ml) for indicated periods of time (min). FGF2 signalling pathway was analyzed. (B) Inhibition of FGFR abrogates FGF2-mediated phosphorylation of RSK2. HB2, SKBR3
and MDA-MB-361 cells were starved with/without FGFR inhibitor (PD173074, 100 nM) and stimulated with FGF2/heparin sulphate. (C) Silencing of FGFR2 negates FGF2-triggered
RSK phosphorylation. HB2, SKBR3 and MDA-MB-361 wild-type and FGFR2 knocked-down mutants were stimulated with FGF2/heparin sulphate. (D) The overexpression of FGFR2 in
MCF7 cells enhances steady-state activity and FGF2-triggered the phosphorylation of RSK2.
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Thr573 (Fig. 2A). This clearly suggests that RSK2 is involved in FGF2-
triggered signalling. To conﬁrm the engagement of RSK2 in FGF2/
FGFR2 signalling pathways cells were incubated with PD173074
(well-characterized, speciﬁc FGFR inhibitor [46,47]) and then stimulat-
ed with FGF2. Pre-treatment with PD173074 nearly completely
abolished the activation of FGFR as well as FGF2-mediated RSKs activa-
tion (Fig. 2B).
To reinforce our conclusion, FGF2-triggered signalling upon FGFR2
silencing in HB2, SKBR3 and MDA-MB-361 cells was analysed. The
knockdown of FGFR2 nearly completely abolished RSK activation. The
effect of FGFR2 silencing on RSK activation in cells expressing other
ﬁbroblast growth factor receptors (FGFR1 and FGFR4) suggests a key
role for FGF2/FGFR2 signalling in RSK phosphorylation (Fig. 2C). To
further substantiate the relationship between RSK2 and FGFR2, we
overexpressed FGFR2 in MCF7 cells (with a moderate level of innate
FGFR2), which resulted in increase in steady-state activity of RSK2 as
well as in enhancement of phosphorylation upon FGF2 treatment
(Fig. 2D). To conﬁrm the role and speciﬁcity of FGF2/FGFR2 signalling
in RSK activation, we also overexpressed FGFR1 in HB2 cells. Treatment
with FGF2 caused the activation of RSK; however, there were no differ-
ences in RSK phosphorylation level between wild-type and FGFR1-
overexpressing cells, which suggests that FGFR1 was not crucial for
RSK activation in mammary epithelial cells (Supplementary Fig. 2).
These let us conclude that RSK2 belongs to the FGF2/FGFR2 signalling
pathway.All further studies that focused on FGF2/FGFR2-RSK interdepen-
dence were done on at least two of three cell lines (HB2, SKBR3 and
MDA-MB-361) presenting a high level of innate FGFR2 expression. Con-
trol experiments were restricted to a single cell line model.3.3. p38 but not ERK or Src activates RSK2 at Tyr529
RSKs are directly activated by several kinases including ERK, Src and
p38 [1]. To identify upstream regulator/s of RSKs inmammary epithelial
and breast cancer cell lines responding to FGF2, cells were treated for
24 hwith speciﬁc inhibitors for individual kinases, i.e., U120 forMEK/ERK,
SU6656 for Src and SB202190 for p38. In all cell lines, p38 inhibition
led to signiﬁcant abrogation of RSK2 phosphorylation at Tyr529, but
not Thr359/Ser363, Thr573 or Ser380 (Fig. 3A).
Therefore, it appears that p38 targets speciﬁcally Tyr529 of the RSK2,
without affecting other RSK isoforms. In accordance with previous
reports [48,49], ERK inhibition affected Thr359/Ser363 and Thr573
(with no effect on RSK2-Tyr529 or RSK-Ser380). Blocking of Src activity
had no apparent inﬂuence on RSK phosphorylation. Efﬁcacies of inhibi-
tors toward targeted kinases were conﬁrmed in a parallel experiment
(Supplementary Fig. 3). In addition, to conﬁrm the speciﬁcity of RSK2
as a target of p38, we demonstrated that the overexpression of p38
kinase in HB2 and SKBR3 cell resulted in enhancement of the activation
of all tested phosphorylation sites (Fig. 3B) with no effect on the level of
protein expression.
Fig. 3. p38 activates RSK2 at Tyr529. (A) RSK2 phosphorylation at Tyr529 depends on p38 but not on ERK or Src activity. MEK/ERK inhibition impairs the activation of RSKs at Thr359/
Ser363 and Thr573. To identify upstream activator of RSKs, HB2, SKBR3 andMDA-MB-361 cells were grown in a complete medium (containing 10% FBS) supplemented with appropriate
inhibitor U120 (10 μM), SU6656 (10 μM) or SB202190 (10 μM) for 24 h. (B) Western blotting shows elevated levels of RSK2 activation in HB2 and SKBR3 cells overexpressing p38.
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ylation of other RSK2 sites
In order tominimize an effect likely to be produced by various growth
factors contained in FBS, cells were starved in serum-free medium, prior
to stimulation with FGF2. Analysis of signalling in HB2 and SKBR3 cells
showed that p38 activity is necessary for FGF2-induced phosphorylation
of RSK2, as inhibition of p38 nearly completely abolished RSK2-Tyr529
phosphorylation (Fig. 4A). In contrast to the previous experimental
setup (cells grown in a complete medium containing FBS) (Fig. 3A), the
phosphorylation of other analyzed RSK residues has followed the activa-
tion of Tyr-529 by p38, i.e., the phosphorylation of Ser380, Thr359/Ser363
and Thr573 by FGF2 in cells pretreated with p38 inhibitor was strongly
impaired. It appears that other growth factors present in the serum
might have activated RSKs, e.g., through ERK signalling (apart from
Tyr529), independently of p38. Importantly, the application of MEK/
ERK inhibitor for analysis of FGF2-triggered pathway did not affect
RSK2-Tyr529 but strongly decreased the phosphorylation of Ser380,
Thr359/Ser363 and Thr573 (Fig. 4B). These results suggest that FGF2
treatment activates two parallel signalling pathways involving RSK2. It
seems that p38, which is a serine/threonine kinase, indirectly activates
RSK2 at Tyr529, which possibly facilitates Thr573, Ser380 and Thr359/
Ser363 activation in the linker region. All RSK phosphorylation sites
studied, except of Tyr529, are additionally phosphorylated by ERK.
To answer the questionwhether p38/RSK2-Tyr529 interdependence
is restricted/speciﬁc to FGF2-mediated signalling, we analyzed EGF-
induced pathway. First, we tested possible RSKs activation upon EGF
treatment in a mammary epithelial cell line (HB2). We found that
RSKs were phosphorylated along with a number of classical down-
stream effectors of EGF, i.e., EGFR, Src, AKT, p38 and ERK (Fig. 4C). Im-
portantly, in contrast to FGF2, where p38 indirectly activated RSK2 at
Tyr529 (which seems to be necessary for the activation of Thr359/
Ser363, Thr573 and Ser380), the inhibition of p38 in the EGF pathway
affected only RSK2-Tyr529, without any effect on other RSKs phosphor-
ylation sites (Fig. 4D). Therefore, it appears that p38-RSK2-Tyr529 is
necessary for the transactivation of residues located at the kinase
linker-region and C-terminal domain in the FGF2/FGFR2 signalling.3.5. RSK2-mediates FGF2-stimulated anchorage-independent growth,
formation of focal adhesions and cell migration
To investigate the functional consequences of RSKs engagement in
FGF2-related signalling, HB2 cells were cultured in soft agarose andtheir potential to grow in anchorage-independentmannerwas assessed.
The presence of FGF2 signiﬁcantly enhanced cell proliferation resulting
in colonies approximately four times bigger than those grown under
control conditions (Fig. 5A and B). The application of FMK (highly specif-
ic and irreversible RSKs inhibitor which binds to the CTKD and inhibits
RSKs autophosphorylation) resulted in an impairment of cell growth
in agarose and nearly completely abolished stimulatory effects of FGF2.
Importantly, the pattern of growth in the presence of FMK resembled
that observed upon p38 inhibition (Fig. 5A and B). The speciﬁcity of
FMK towards RSK2-Tyr529 activation has been additionally conﬁrmed
(Supplementary Fig. 4). It appears, therefore, that p38-RSK2 axis medi-
ates the stimulatory effect of FGF2 on adhesion-independent growth.
An increasing evidence strongly implicates RSK2 in cell migration. A
comparative analysis of HB2 cell migration towards medium supple-
mented with FBS alone (control) and FBS containing FGF2 demonstrated
that the latter induced migration of around 40% more cells. To analyze
whether RSK2 is involved in FGF2-stimulated motility we pretreated
cells with FMK. This resulted in a strong inhibition of migratory potential
towards both control and FGF-containing media, thus indicating that
RSKs are crucial for cell migration including that stimulated by FGF2
(Fig. 5C). The dynamic assembly and disassembly of focal adhesions
plays a central role in cell migration. To further investigate an involve-
ment of RSKs in cell motility we analyzed the properties of FAs in cells
under various conditions. SKBR3 and HB2 cells treated for 1 h with
FGF2 were stained for paxillin and FAK. Distributions of both paxillin
and FAK at the characteristic assemblies indicated that FGF2-induced for-
mation of new focal adhesions (Fig. 5D and Supplementary Fig. 5). In ad-
dition, paxillin and FAK were shown to be activated by FGF2 (Fig. 5E),
whichmight provide an explanation for the FGF2's role in the promotion
of cell migration. Importantly, signiﬁcant amounts of RSK2were found in
the adhesive assemblies of FGF2-stimulated cells. Moreover, pretreat-
ment of the cells with FMK not only prevented FGF2-induced localization
of RSK2 within the focal adhesions but also generally decreased focal
adhesion number in both examined cell lines (Fig. 5D and Supplemen-
tary Fig. 5). Taking together, an involvement of RSK2 in anchorage-
independent growth, focal adhesion dynamics and cell motility upon
FGF2 stimulation strongly implicates RSK2 in breast cancer progression.
4. Discussion
4.1. Mechanism of RSKs activation
RSKs are activated in the canonical and alternative pathways. In the
canonical path, sequential events necessary for RSKs activation are
Fig. 4. The activation of RSK2-Tyr529 by p38 mediates the phosphorylation of other RSK2 sites in FGF2/FGFR2 signalling. (A) p38 activity is necessary for FGF2-triggered the activation of
RSK2. HB2 and SKBR3 cells were starved in serum-free media with or without p38 inhibitor (SB202190, 10 μM). As indicated, cells were stimulated with FGF2 (10 ng/ml) + heparin sul-
phate (10 ng/ml) for 10 or 60min. (B)MEK/ERK inhibition (U120, 10 μM)does not affect RSK2-Tyr529 but strongly decreases thephosphorylation of Ser380, Thr359/Ser363 and Thr573 in
HB2 cells. C) RSK2 is activated upon EGF stimulation—Western blotting of EGFR/EGF signalling pathway including Src, AKT, p38, ERK and RSK in HB2 cells. (D) Inhibition of p38 abolishes
RSK2-Tyr529 activation but does not affect other RSKs phospho-sites at EGF-driven signalling.
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Active ERK phosphorylates RSKs at Thr573 in CTKD and, subsequently,
at Ser363 and Thr359 in the linker region. Activated CTKD induces the
autophosphorylation of Ser380 (linker region), which creates a docking
site for PDK1, leading to the activation of NTKD by phosphorylating
Ser221of RSKs and,ﬁnally, enablingRSKs tophosphorylate and regulate
target proteins [1,18]. The alternative, much less understood mecha-
nisms of RSKs activation are based on the stabilized association between
ERK1/2 and RSK2. According to Kang et al. [23], in hematopoietic cells,
FGFR3 directly phosphorylates RSK2 at Tyr529. In kidney cells, RSK2 is
phosphorylated at Tyr529 by Src and Fyn in response to EGF stimulation
[50]. As suggested by both studies, the phosphorylation of RSK2 at Tyr-
529 facilitates binding of inactive ERK to RSK2 and subsequent ERK-
related phosphorylation of residues within the CTDK and the linker
region. In dendritic cells, apart from ERK1/2-mediated phosphorylation,
RSKs are also activated by p38 throughMK2 (MAPK-activated kinase-2)
or MK3 [51].Results of our studies of RSKs activation in mammary epithelial and
breast cancer cells indicate the presence of two parallel mechanisms of
RSK2 activation in the FGF2/FGFR2 signalling axis: a canonical, focused
on ERK action and an alternative, with RSK2 phosphorylation at
Tyr529 involving the activity of p38 (Fig. 6). As a serine/threonine
kinase, p38 cannot directly phosphorylate RSK2 at Tyr529. There must
be, therefore, additional mediator/s with tyrosine kinase activity to-
wards RSK2 laying down of p38. To our knowledge no such tyrosine
kinase downstream of p38 has been identiﬁed yet.
As suggested by Kang et al. [23], the activation of RSK2 at Tyr529
promotes ERK-driven phosphorylation of other RSK2 residues
(i.e., Thr573, Thr359/Ser363 and Ser380) through a mechanism inde-
pendent of cell speciﬁcity. Indeed, as supported by our observation,
p38 inhibition in the FGF2/FGFR2 pathway abolished RSK phosphoryla-
tion at all studied residues. The proposed sequential activation of RSK2,
involving the action of p38, appears to be speciﬁc for the analyzed path-
way. In the EGF-triggered signalling, inhibition of p38 abolished only
Fig. 5. p38-RSK2 axis mediates FGF2-driven cellular activities. (A and B) RSKs mediate FGF2-stimulated anchorage-independent growth. HB2 colonies were cultured in soft agarose in
media supplementedwith FGF2 (10 ng/ml)+ heparin (10 ng/ml), RSKs inhibitor FMK (2 μM) and/or p38 inhibitor SB202190 (10 μM). Pictures were taken after 21 days of culture. Mea-
surement of colonies size (diameter) (B) was donewith ImageJ. The values presented are means± SD (n=3), *p=2× 10−4 in relation to control, **p=3× 10−3 and ***p=1× 10−3,
both in relation to FGF2-treated cells. (C) FGF2-induced cell migration involves RSKs action. HB2 cells migrated towards medium supplemented with FGF2 ± FMK. The values presented
are means ± SD (n= 3), *p= 4 × 10−3 in relation to control, **p= 2 × 10−4 in relation to FGF2-treated cells. (D) FGF2 stimulation promotes formation of focal adhesions with the in-
volvement of RSK2. HB2 cells were starved overnight and stimulatedwith FGF2 (10 ng/ml)+ heparin sulphate (10 ng/ml) for 1 hwere ﬁxed on glass coverslips and immunostainedwith
antibodies against paxillin, FAK or RSK2. (E) The activation of FAK and paxillin upon FGF2 stimulation of HB2 cells was conﬁrmed by Western blotting.
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sites (Fig. 4D). Thus, RSK2-Tyr529 phosphorylation in the EGF signalling
is probably not indispensable for RSK2 activation, or phosphorylation of
other sites can be easily compensated by ERK activity towards RSKs.
Surprisingly, we did not observed any effect of Src inhibition, which in
kidney cells was shown to abolish RSK2 function [50]. This discrepancy
might result from various, growth factor-speciﬁc mechanisms of RSK2
activation and/or might be due to cell speciﬁcity of RSKs' regulation.
4.2. Cellular effects
Cell adhesion, spreading and migration on extracellular matrix are
primarily based on coordinated signal transduction from adhesion
receptors to the cytoskeleton. The crosstalk between growth factor re-
ceptors and adhesion receptors (e.g., integrins) controls speciﬁc cellular
responses to the stimuli originating in the extracellular environment.
We have found that RSK2 phosphorylation is triggered by FGF2/FGFR2
signalling and mediates a number of cellular effects attributed to the
activation of this pathway. Despite existence of conﬂicting data and
the lack of full elucidation of underlying mechanisms of its action,
FGFR2 is undeniably involved in breast cancer development and
progression [26,40]. Here we have shown that RSK2 is one of the down-
stream effectors in FGFR2 signalling and contributes to cancer cells
anchorage-independent growth and motility, which is consistent with
previous reports linking RSK isoforms with a number of processes incancer progression [11,52,53]. RSKs affect migratory processes by both
(i) the direct effects involving the function of adhesion receptors and
cytoskeleton`s dynamics and (ii) the indirect effects associated with
regulation of gene transcription.
Direct engagement of RSKs in cellular activities is associated with
actin-binding protein, ﬁlamin A, which has been identiﬁed as a phos-
phorylation substrate for both RSK1 and RSK2 [54]. Filamin A interacts
with the cytoplasmic tail of β1 integrin facilitating the interaction
between an adhesion receptor and the cytoskeleton [55]. RSK2 has
been reported to mediate also Ras/Raf-dependent inactivation of
integrins which results in an impairment of cell adhesion and integrin-
mediated matrix assembly and, eventually, increase in cell motility
[53]. The integrin cytoplasmic tail associates with the cytoskeletal
proteins including talin and ﬁlamin A. RSK2 has been found to alter
talin localization in focal adhesions and to promote ﬁlamin A phosphory-
lation which triggered ﬁlamin binding to β1 and β7 integrin cytoplasmic
domains [53]. Moreover, RSKs were demonstrated to phosphorylate
ﬁlamin A at Ser2152 in membrane rufﬂes during cell migration [54].
Abrogation of RSK2 activity blocked Ras effects on integrin activation,
suggesting that RSK2 phosphorylation of ﬁlamin A is a primary mediator
of Ras/ERK-dependent regulation of integrin-mediated cell adhesion and
motility. RSK2was also shown to be activated during cells adhesion to ﬁ-
bronectin, suggesting a possible feedback loop enabling cell attachment
to and detachment from ﬁbronectin during migration [53]. Although
this study showed that active RSK2 disrupted focal adhesions, it did not
Fig. 6. A schematic model of FGF2/FGFR2-triggered RSK2 activation in mammary epithelial and breast cancer cells. In the proposed model, RSK2 is activated by two parallel mechanisms
following the FGFR2/FGF2 activation: (i) canonical, with the involvement of ERK, and (ii) alternative, in which p38mediates RSK2-Tyr529 phosphorylation through an unknown tyrosine
kinase facilitating binding of inactive ERK to RSK2 and subsequent phosphorylation of other phospho-sites, resulting in a complete RSK2 activation.
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lated disaggregation of the focal adhesion complex. Our results demon-
strated that FGF2 treatment of serum starved cells resulted in RSK2,
FAK and paxillin relocalization to the focal adhesions. The inhibition of
RSKs activity nearly completely prevented RSK2 shift to the area of
focal contacts and impaired localization of FAK and paxillin. These data
together with work published by Gawecka et al. clearly suggest that
RSK2 is involved in the dynamics and turnover of proteins within the
focal adhesions.
RSK2 was shown to directly phosphorylate Hsp27 in HNSCC cells
[11]. Hsp27 has been implicated in regulation of cytoskeleton dynamics
by stabilizing actin ﬁlaments [56], which is consistent with the sug-
gested role for RSK2 in invasive behaviour of HNSCC cells. Interestingly,
the knockdown of RSK2 in the same cells resulted in an impaired activa-
tion of FAK [11], implicated in the regulation of cell migration through
effects on actin remodelling andassembly of focal adhesions. This obser-
vation is in agreement with our ﬁnding demonstrating FAK activation
and localization in focal adhesions in an RSK2-dependent manner in
response to the FGF2 treatment.
The interdependence between adhesion and growth factor receptors
involving RSKs activity has been already reported. EGF was found toactivate ERK/RSK in squamous cell carcinoma and colon cancer cells
leading to the phosphorylation of ﬁlamin A and inactivation of α5β1
integrin. These resulted in loss of α5β1-dependent adhesion of cancer
cells to ﬁbronectin, providing an additional evidence for RSKs' involve-
ment in the function of integrins [57]. Our data demonstrate an engage-
ment of RSKs, with a prominent role of RSK2, in FGF2/FGFR2-dictated
cellular effects including formation of focal adhesions and cell migra-
tion. Therefore, it is highly possible that RSK2 connects FGF2/FGFR2
pathway with integrins' activity and hence enhances cell motility.
Besides their direct function in cell adhesion andmigration, RSK iso-
forms have been shown to exert a profound effect on the transcriptional
program modulating cell motility and invasion. A series of genome-
wide mRNA expression analyses revealed that among 1089 genes
affected by ERK in epithelial cells, RSKs regulated expression of
228 genes. Strikingly, among the RSKs-affected mRNAs, genes with
established roles in motility and invasion comprised the largest func-
tional group (~25%) [22]. Indeed, RSK1/2 were found to activate a tran-
scriptional program that is thought to coordinately modulate the
extracellular environment, the intracellular motility apparatus and
receptors-mediated communication with the cytoskeleton. Another
genome-wide RNAi screen of 11,000 genes identiﬁed 31 targets,
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tion. Chemical inhibition of RSKs dramatically inhibited epithelial cell
motility triggered by silencing of all 31 genes [58]. Among a number
of RSK2 targets, a transcription factor CREB (cAMP response element-
binding protein) was found to be phosphorylated by RSK2 [15]. RSK2-
CREB pathway has been conﬁrmed to be commonly activated in diverse
metastatic human cancer cell lines, leading to upregulation of CREB
transcription target—fascin-1 (the only actin-bundling protein that lo-
calizes along the entire length of ﬁlopodia) [59]. RSK2 expression, the
activation of CREB and fascin-1 levels have been positively correlated
in HNSCC tumours. The knockdown of RSK2 was shown to disrupt
ﬁlopodium activities during HNSCC cell in vitro invasion and formation
of in vivometastases, which was reverted by RSK2 re-expression [59].
RSK2 signalling was also found important in providing protection
from anoikis (one of the hallmarks of invasive cancers) to metastatic
cells from diverse epithelial tumours, including lung, breast and head
and neck cancers [52]. Consistent with this role, our data demonstrated
that FGF2 via RSK2-mediated effects promoted anchorage-independent
survival and growth of the cells.
5. Summary
Here we found that FGF2/FGFR2 signalling induced the activation of
RSK2 at Tyr529 indirectly by p38 kinase in normal epithelial mammary
and breast cancer cell lines. This triggered the activation of other phos-
phorylation sites within the CTKD and the linker region of RSK2. Analy-
ses of the role of RSK2 in cellular effects mediated by FGF2 revealed that
RSK2 was involved in mediation of dynamics of focal adhesions. This
was reﬂected by enhancement of RSK-dependent cell migration to-
wards FGF2 likely to involve a crosstalk between FGF2/FGFR2 signalling
pathway and adhesion receptors (e.g., integrins). RSK2 was also crucial
for FGF2-stimulated anchorage-independent growth. All observed pro-
migratory behaviours seemed to be directly resulting from the activa-
tion of RSK2 (short exposure to FGF2), whereas engagement of RSK2
in anchorage-independent growth appeared to be associated with its
involvement in FGF2-regulated gene expression. In light of emerging
evidence for the role of FGFR2 in breast cancer progression, our ﬁndings
might have important clinical implications and contribute to creation of
foundations for development of new therapeutic strategies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.06.022.
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